title: Home therapy with subcutaneous anti-immunoglobulin-E antibody omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma.
authors: Sansum Clinic, Santa Barbara, CA, USA. mliebhab@sansumclinic.org
authors: Myron
authors: M
authors: Liebhaber
authors: Zeb
authors: Z
authors: Dyer
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology*; D005260:Female; D006699:Home Care Services; D006801:Humans; D006967:Hypersensitivity / Q000150:complications*; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E